Development and characterization of single domain monoclonal antibody against programmed cell death ligand-۱; as a cancer inhibitor candidate

سال انتشار: 1401
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 225

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-25-3_006

تاریخ نمایه سازی: 15 فروردین 1401

چکیده مقاله:

Objective(s): One of the important interactions in controlling the human immune system is the reaction between checkpoint proteins such as programmed cell death-۱ (PD-۱) and its ligand, PD-L۱. These are negative immunoregulatory molecules that promote immune evasion of tumor cells. PD-L۱ expression is an immune-mediated mechanism used by various malignant cells in order to down-regulate the immune system. Checkpoint inhibitors (CPIs) are a new class of anti-cancer agents that stimulate immune cells to elicit an antitumor response by blocking the ligand and receptor interactions. Nanobody (Nb) as a new type of antibody fragment, has some potential as CPI.Materials and Methods: A female camel was immunized with recombinant PD-L۱ protein, nanobody library was constructed and PD-L۱ specific Nb was selected. The selected Nb was characterized in terms of affinity, specificity, and binding potency in ELISA, Western blotting, and flow cytometry. Results: Developed nanobody, A۲۲ binds to its cognate target with high specificity and affinity. Western blot and flow cytometry techniques showed that nanobody A۲۲ was able to specifically detect and attach to human PD-L۱ protein on the cell surface and in the cell lysate. MTT assay showed the inhibitory effect of PD-L۱ by specific Nb on A۴۳۱ and HEK۲۹۳ cells, with no cytotoxic effect on cell growth.Conclusion: The results highlighted the potential of anti-PD-L۱ Nb as a novel therapeutic in cancer therapy without undesirable cytotoxicity.

کلیدواژه ها:

Cancer ، Checkpoint inhibitors ، Nanobody ، Programmed cell death - ligand-۱ ، Single domain antibody

نویسندگان

Akbar Oghalaei

Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Feriedon Mahbudi

Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Fatemeh Rahimi Jamnani

Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran

Somayeh Piri-Gavgani

Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran

Fatemeh Kazemi-Lomedasht

Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Aida Hassanzadeh-Eskafi

Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Delavar Shahbazzadeh

Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Ahmad Adeli

Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Yeganeh Talebkhan

Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Mahdi Behdani

Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Kazemi-Lomedasht F, Muyldermans S, Habibi-Anbouhi M, Behdani M. Design of ...
  • Weber J. Immune checkpoint proteins: a new therapeutic paradigm for ...
  • Dong H, Zhu G, Tamada K, Chen L. B۷-H۱, a ...
  • Dzik S, Aubuchon J, Jeffries L, Kleinman S, Manno C, ...
  • Jiang X, Wang J, Deng X, Xiong F, Ge J, ...
  • Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, ...
  • ۷.Hofmeyer KA, Jeon H, Zang X. The PD-۱/PD-L۱ (B۷-H۱) pathway ...
  • Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, ...
  • Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. ...
  • Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, ...
  • Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, ...
  • Tewalt EF, Cohen JN, Rouhani SJ, Guidi CJ, Qiao H, ...
  • Bagheri M, Babaei E, Shahbazzadeh D, Habibi-Anbouhi M, Alirahimi E, ...
  • Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, ...
  • Khodabakhsh F, Behdani M, Rami A, Kazemi-Lomedasht F. Single-Domain Antibodies ...
  • ۱۶.De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as ...
  • Van Audenhove I, Gettemans J. Nanobodies as versatile tools to ...
  • Sadeghi A, Behdani M, Muyldermans S, Habibi-Anbouhi M, Kazemi-Lomedasht F. ...
  • Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody ...
  • Alirahimi E, Ashkiyan A, Kazemi-Lomedasht F, Azadmanesh K, Hosseininejad-Chafi M, ...
  • van der Schoot JMS, Fennemann FL, Valente M, Dolen Y, ...
  • Jovčevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs ...
  • Poullin P, Bornet C, Veyradier A, Coppo P. Caplacizumab to ...
  • Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier ...
  • D’huyvetter M, Aerts A, Xavier C, Vaneycken I, Devoogdt N, ...
  • Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, ...
  • Pruszynski M, D’Huyvetter M, Bruchertseifer F, Morgenstern A, Lahoutte T. ...
  • Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, ...
  • Xavier C, Blykers A, Vaneycken I, D’Huyvetter M, Heemskerk J, ...
  • Choi J, Vaidyanathan G, Koumarianou E, Kang CM, Zalutsky MR. ...
  • Kazemi-Lomedasht F, Behdani M, Bagheri KP, Habibi-Anbouhi M, Abolhassani M, ...
  • Li S, Jiang K, Wang T, Zhang W, Shi M, ...
  • Zhang F, Wei H, Wang X, Bai Y, Wang P, ...
  • نمایش کامل مراجع